Munich, Germany

Ludwig Deml

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Geneart Ag. Active years: 2008-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ludwig Deml. Retrieved from https://idiyas.com/inventor/ludwig-deml-nirlmxzo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2008-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ludwig Deml: Innovator in Synthetic Gagpol Genes

Introduction

Ludwig Deml is a notable inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of synthetic gagpol genes. With a total of 2 patents, his work has implications for vector particle generation and vaccine development.

Latest Patents

Deml's latest patents focus on synthetic gag and gagpol genes optimized for high-level expression through codon optimization. These inventions are crucial for the efficient generation of vector particles. Furthermore, they relate to the creation of packaging cells and vaccines based on these synthetic genes.

Career Highlights

Ludwig Deml is associated with Geneart AG, a company that specializes in genetic engineering and biotechnology. His work at Geneart AG has positioned him as a key player in the advancement of genetic research and applications.

Collaborations

Throughout his career, Deml has collaborated with notable colleagues, including Ralf Wagner and Kurt Bieler. These partnerships have enhanced his research and contributed to the success of his inventions.

Conclusion

Ludwig Deml's innovative work in synthetic gagpol genes showcases his expertise and commitment to advancing biotechnology. His contributions are paving the way for future developments in genetic engineering and vaccine technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…